ClinicalTrials.gg

Program

RAS/PI3K-alpha Inhibitor VVD-159642

Its studies are led by Bayer.

Furthest: phase 1, since Jan 27, 20251 company-led study, 1 open or runningNext primary completion: Aug 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer11 open or runningphase 1since Jan 27, 2025Jan 27, 2025Aug 1, 2027phase 1 · NCT06804824

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06804824 · 220 planned · United States, Australia

Ahead

  1. Aug 1, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06804824

TargetBeta

PIK3CA →read by rule
“An orally bioavailable inhibitor of RAS-driven phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3K-alpha; PI3Ka; PIK3CA) activity, ”NCIt, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06804824Advanced Solid Tumors · United States, Australia1RecruitingAug 1, 2027220

How it is read

Names in the registry

  • “VVD-159642”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.